Titlebook: Substance Use Disorders; From Etiology to Tre Michael A. Nader,Yasmin L. Hurd Book 2020 Springer Nature Switzerland AG 2020 Substance Use D

打谷工具

Clinical Trials for Stimulant Use Disorders: Addressing Heterogeneities That May Undermine Treatmencations for stimulant use disorders. One contributing factor may involve heterogeneity. At the neurobiological level, dual dopamine dysfunction may be undermining medication efficacy, suggesting a need for combination pharmacotherapies. At the population level, individual variability is expressed in

辩论

Molecular Mechanism and Cannabinoid Pharmacology,ation of its major cannabinoid constituents, Δ.-tetrahydrocannabinol (THC) and cannabidiol (CBD), led to the synthesis of new cannabinoids (termed synthetic cannabinoids) to understand the mechanisms underlying the pharmacology of .. These pharmacological tools were instrumental in the ultimate disc

边缘带来墨水

Pharmacotherapies for Cannabis Use Disorders: Clinical Challenges and Promising Therapeutic Agents,ittle or uncertain value. A diverse range of medicines have been tested, representing a broad range of pharmacological strategies. These include tetrahydrocannabinol preparations, various types of antidepressant, anxiolytics, a glutamatergic modulator and the neuropeptide oxytocin. Cannabinoid agoni

Humble

Molecular Mechanisms Associated with Nicotine Pharmacology and Dependence, also been garnering increased popularity in its vaporized form, as derived from e-cigarette devices. Thus, an understanding of the molecular mechanisms underlying nicotine pharmacology and dependence is required to ascertain novel approaches to treat drug dependence. In this chapter, we review the

Pathogen

学术讨论会

Diluge

不出名

肥料

低能儿

Molecular Mechanisms of Amphetamines, PKC, CaMKII, and OCT3. As is generally true for the development of therapeutics for substance use disorder, there are multiple preclinically promising specific compounds against (meth)amphetamine, for which further development and clinical trials are badly needed.